Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Idiopathic Parkinson DiseaseParkinson's Disease and Parkinsonism
Interventions
GENETIC

Adipose-derived stromal vascular fraction cells

Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.

Trial Locations (1)

Unknown

Hospital Escuela Oscar Danilo Rosales Arguello, León

All Listed Sponsors
collaborator

Wake Forest University

OTHER

collaborator

Ministerio de Salud, Nicaragua

UNKNOWN

collaborator

GID BIO, Inc.

INDUSTRY

collaborator

National Autonomous University of Nicaragua

OTHER

lead

Samuel Vilchez, PhD

OTHER

NCT05699161 - Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson | Biotech Hunter | Biotech Hunter